Yüklüyor......
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
PURPOSE: Omacetaxine mepesuccinate is a first-in-class cephalotaxine demonstrating clinical activity in chronic myeloid leukemia. A subcutaneous (SC) formulation demonstrated efficacy and safety in phase 1/2 trials in patients previously treated with ≥1 tyrosine kinase inhibitor. This study assessed...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer-Verlag
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3535355/ https://ncbi.nlm.nih.gov/pubmed/23053254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1963-2 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|